NS Pharma Inc.

01/30/2026

This is exciting progress for the Duchenne community.

Newborn screening has the power to change lives through earlier identification and earlier support for families. Adding Duchenne muscular dystrophy to the Recommended Uniform Screening Panel (RUSP) is a meaningful step toward more consistent screening and earlier care across states.

We’re encouraged to see continued education and resources that help move this important conversation forward and keep families at the center.

🆕 Introducing the Newborn Screening Resource Roadmap.

❓ Is the condition present in early childhood? Is it currently screened for by any U.S. state?

These questions and more can help you better understand the evidence development behind newborn screening and what is needed to add conditions to state panels.

For more than 50 years, every newborn in the U.S. has been screened for a range of debilitating and deadly diseases through a simple heel prick. Each year, 12,000 babies and their families benefit from early detection and life saving treatments made possible by newborn screening.

The Newborn Screening Resource Roadmap is designed to help anyone new to newborn screening navigate key topics and resources so that you can advocate effectively for newborn screening in your state.

🔗 Learn more and check out our new Roadmap here: https://everylifefoundation.org/newborn-screening-take-action/newborn-screening-resource-roadmap/

01/26/2026

We are looking forward to WORLDSymposium 2026, where the global lysosomal disease community comes together to share science, insights, and progress.

NS Pharma is proud to be presenting at this year’s meeting, contributing to important conversations focused on advancing research and care for individuals living with rare genetic conditions.

We value the opportunity to engage with clinicians, researchers, and advocates who are dedicated to improving outcomes across the rare disease landscape.

If you haven't already, register here: https://ow.ly/xVLP50Y3CtS

01/21/2026

We’re proud to support ongoing clinical research to improve the lives of people living with Duchenne muscular dystrophy (DMD).

Among the trials we sponsor is Brogidirsen (NS-089/NCNP-02), which recently presented 3.5-year efficacy and safety data at the 2025 World Muscle Society Congress.

If you or someone you care for is interested in learning more or participating in a DMD clinical trial, visit our clinical trials page for details and eligibility information:
https://ow.ly/tq9s50Y0xOy

01/14/2026

We are happy to be heading to Miami, FL for the upcoming CureDuchenne Workshop! 💙

This gathering offers a welcoming space for families, caregivers, clinicians, and researchers to come together and explore the latest insights in Duchenne muscular dystrophy. It is a great chance to learn, ask questions, and connect with others who share the same hope for progress.

📅 Date: Saturday, January 17, 2026
🕗 Time: 8:00 AM to 4:00 PM
📍 Location: Miami Marriott Dadeland, 9090 S Dadeland Blvd, Miami, FL 33156

Register and learn more: https://ow.ly/K9wp50XWBs7

We look forward to seeing everyone there and taking part in a day of learning and connection.!

01/12/2026

As we begin 2026, we are looking ahead with purpose and continuing to grow our team at NS Pharma.

We are currently hiring a Senior Director, Market Access - an opportunity for an experienced leader who is passionate about improving access to therapies for people living with rare diseases. This role plays a key part in supporting patients and families by helping navigate the evolving healthcare landscape.

If you are looking to take the next step in your career and make a meaningful impact, we invite you to learn more and apply:
🔗 https://ow.ly/n7iM50XVpW3

01/08/2026

We are looking forward to connecting with the Duchenne community in Memphis at the upcoming CureDuchenne Community Dinner! 💙

This special evening is for families, caregivers, and advocates impacted by Duchenne muscular dystrophy. It's an amazing opportunity to share experiences, ask questions, and spend time with others who understand the journey.

📅 Date: January 10, 2026
🕕 Time: 6:00 PM to 9:00 PM
📍 Location: Fleming’s Prime Steakhouse, 6245 Poplar Avenue, Memphis, TN 38119

👉 Reserve your spot: https://ow.ly/aLvt50XTmhK

01/06/2026

The dystrophin gene has 79 sections, called exons. Exon-skipping therapies work by “skipping” a specific exon, which can help the body compensate for certain mutations.

A simple genetic test can identify which exons are affected and whether exon-skipping may be an option.

Talk with your doctor to arrange a test, and learn more about DMD here: https://ow.ly/vgzg50XJwHY

12/22/2025

As the year comes to a close, we extend our heartfelt thanks to our colleagues, friends, and families across the rare disease community. 💙

Your collaboration and commitment continue to inspire our work and drive progress for everyone we serve.

From all of us at NS Pharma, we wish you a joyful holiday season filled with peace, rest, and connection.

12/17/2025

Did you know that Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare and often misunderstood condition? 🕵️‍♂️

Previously known as Churg-Strauss Syndrome, this is characterized by a mix of symptoms including asthma, sinusitis, skin rashes, and nerve pain, making it hard to diagnose due to its rarity and symptom overlap with other diseases.

The good news? At NS Pharma, we’re actively working to change that! Our promising compound, NS-229, is currently in phase 2 clinical trials, with the potential of bringing new hope to those affected.

Learn more about our innovative research here: https://ow.ly/EouG50XJw4i

12/10/2025

Dystrophin is a vital protein that helps muscles stay strong and protected as they contract and relax.

For people with Duchenne muscular dystrophy (DMD), a genetic mutation prevents the body from making usable dystrophin. Without it, muscles become more vulnerable to damage and grow progressively weaker over time.

Because the heart is a muscle and muscles also help support the lungs, the impact of Duchenne goes beyond mobility, it can lead to serious health challenges as the condition progresses.

Learn more about DMD here: https://ow.ly/BoX250XGNQn

12/05/2025

We’re looking forward to connecting with the Duchenne community in Phoenix at the upcoming CureDuchenne Community Dinner! 💙

This special evening brings together families, caregivers, and advocates to share experiences, exchange knowledge, and strengthen support for those living with Duchenne muscular dystrophy.

📅 Date: December 6, 2025
🕕 Time: 6:00 PM – 9:00 PM
📍 Location: Phoenix, AZ

Reserve your seat and be part of the conversation: https://ow.ly/tGe850XCH9K